Accuray Incorporated (NASDAQ:ARAY) Sees Significant Growth in Short Interest

Accuray Incorporated (NASDAQ:ARAY - Get Free Report) was the recipient of a large increase in short interest in January. As of January 31st, there was short interest totalling 4,500,000 shares, an increase of 11.7% from the January 15th total of 4,030,000 shares. Based on an average trading volume of 740,500 shares, the short-interest ratio is currently 6.1 days.

Accuray Stock Up 0.7 %

ARAY stock traded up $0.02 during midday trading on Tuesday, reaching $2.25. The company had a trading volume of 337,434 shares, compared to its average volume of 785,280. Accuray has a 1 year low of $1.40 and a 1 year high of $2.95. The company has a current ratio of 1.62, a quick ratio of 0.87 and a debt-to-equity ratio of 3.51. The company has a market capitalization of $230.85 million, a P/E ratio of -44.90 and a beta of 1.51. The company has a 50 day moving average of $2.14 and a two-hundred day moving average of $1.99.

Accuray (NASDAQ:ARAY - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.03. Accuray had a negative return on equity of 9.75% and a negative net margin of 0.96%. On average, equities research analysts expect that Accuray will post 0.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Accuray

Several institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC acquired a new position in Accuray in the second quarter worth approximately $30,000. Ameriprise Financial Inc. acquired a new position in shares of Accuray during the 4th quarter worth $35,000. US Bancorp DE raised its holdings in shares of Accuray by 1,087.7% during the 3rd quarter. US Bancorp DE now owns 17,816 shares of the medical equipment provider's stock valued at $32,000 after purchasing an additional 16,316 shares in the last quarter. Caprock Group LLC acquired a new stake in shares of Accuray in the 3rd quarter valued at $36,000. Finally, Prudential Financial Inc. bought a new stake in Accuray in the fourth quarter worth $43,000. 64.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, StockNews.com downgraded Accuray from a "buy" rating to a "hold" rating in a research note on Tuesday.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.